About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Management Company Invests $170 Million to Advance Aortic Disorder Treatment

New York, NY, April 5, 2017 – Deerfield Management Company announced today that it has committed to provide up to $170 million to Endologix, Inc. in a combination of senior secured notes and a working capital facility.  

Endologix is a marketer and developer of innovative, minimally invasive technologies that provide personalized treatments to patients suffering from Abdominal Aortic Aneurysms (AAA).  The company’s unique approach to addressing key issues, such as challenging anatomies, difficult access, and aneurysm sealing, provides patients with improved outcomes and may reduce procedure length and hospital stay with Endovascular Aneurysm Repair (EVAR), Percutaneous Endovascular Aneurysm Repair (PEVAR), and Endovascular Aneurysm Sealing (EVAS) procedures.

The facility provided by Deerfield is comprised of $120 million of senior secured notes and a $50 million revolving line of credit.  Warrants to purchase 6.47 million shares were included as part of the senior notes.  This financing provides Endologix with capital to retire certain existing debt, as well as fund its development and marketing of EVAR, PEVAR, and EVAS platforms and its procedure planning software.

“We believe Endologix’s portfolio provides a broad and innovative range of options for treating AAA patients, from relatively routine cases to complex disease. As recently launched products continue to gain traction and the pipeline matures, we expect Endologix to play an important role in enhancing the standard of care, especially in patients with difficult-to-treat disease,” stated Avi Kometz, Partner at Deerfield Management Company.

 “We are excited to partner with Deerfield, a leading healthcare investor, to advance our groundbreaking AAA technologies by providing a broad and flexible financing solution to fit our needs,” remarked Vaseem Mahboob, Chief Financial Officer at Endologix, Inc.  “Deerfield’s creative and collaborative process led to a complete financing package that will address both our financing and market research needs.”

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders.  The Company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA).  AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement.  Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture.  The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States.  For more information, visit

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.  For more information, please visit 


Deerfield Management Company
Karen Heidelberger, 212-692-7140
[email protected]